Key result
Incidental pulmonary embolism in cancer patients was associated with a higher risk of long-term all-cause mortality compared to those without incidental pulmonary embolism.
Why the study?
The effect of incidental pulmonary embolism on long-term prognosis in cancer patients is unclear.
Does incidental pulmonary embolism increase long-term mortality in cancer patients?
Cohort (n=13,371)
No
Does incidental pulmonary embolism increase long-term mortality in cancer patients?
Incidental pulmonary embolism in cancer patients is associated with a more than two-fold increased risk of long-term all-cause mortality, driven primarily by cancer-related rather than thrombosis-related factors.
Answers are grounded in this paper and cite their sources.
Incidental PE in cancer patients needs cautious prognostic interpretation; leaves open independent survival impact pending prospective data.
BACKGROUND: The effect of incidental pulmonary embolism (PE) on long-term prognosis in cancer patients is unclear. This study assessed the characteristics of cancer and venous thromboembolism (VTE) and the effect of incidental PE identified by oncologists on long-term survival of patients with cancer. METHODS AND RESULTS: This single-center, retrospective, cohort study used hospital-based cancer registry data from the Osaka International Cancer Institute linked with electronic medical records and administrative data from Japan's Diagnosis Procedure Combination Per-diem Payment System. Overall, 15,689 cancer patients underwent contrast-enhanced thoracic computed tomography during 2010-2018. After excluding patients with missing data, symptomatic patients, or patients with suspected PE, 174 with incidental PE (PE+ group) and 13,197 with no PE (PE- group) were identified. The total incidence of incidental PE was 1.3%. No deaths from thrombotic events were identified in the PE+ group. Both groups were adjusted for cancer- and VTE-related characteristics using inverse probability weighting. After adjusting for immortal time bias in the PE+ group, Kaplan-Meier analysis revealed that all-cause mortality was higher in the PE+ group (hazard ratio, 2.26; 95% confidence interval, 1.53-3.33). A Cox proportional hazard model revealed that metastatic cancer and a history of curative treatment were significant prognostic factors, whereas central PE and residual proximal deep vein thrombosis were not. CONCLUSIONS: Incidental PE in cancer patients indicates poorer prognosis. Cancer-related but not thrombosis-related factors determine prognosis.
No takes yet. Share an insight, caveat, or question.
Nishikawa et al. (2021) conducted a cohort in Cancer (n=13,371). Incidental pulmonary embolism vs. No incidental pulmonary embolism was evaluated on Long-term all-cause mortality (HR 2.26, 95% CI 1.53-3.33, p=<0.001). Incidental pulmonary embolism in cancer patients was associated with a higher risk of long-term all-cause mortality compared to those without incidental pulmonary embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: